Promakhos Therapeutics is excited to announce today that the company will receive an early seed investment from the Allston Venture Fund.
Early March, the company presented its vision and scientific mission to the Allston Venture Fund Committee, which is made up of 6 partners from different venture firms operating in Massachusetts. Afterwards, the company received an unanimous decision by the Commitee to fund the company.
Although companies can present to the Allston Venture Fund through the Harvard Innovation Labs Venture Program, the fund operates independently from Harvard University and its independent committee is solely responsible for all investment decisions. No Harvard employee, faculty member or student serves on the Allston Venture Fund Committee.